6,568 results match your criteria Acta Oncologica[Journal]


Bone versus soft-tissue setup in proton therapy for patients with oesophageal cancer.

Acta Oncol 2022 Jul 1:1-10. Epub 2022 Jul 1.

Department of Medical Physics, Aarhus University Hospital, Aarhus, Denmark.

Background: The aim of this study was to investigate the effect of patient positioning based on either bone or soft-tissue matching for PT in oesophageal cancer and its impact on plan adaptation.

Materials And Methods: Two retrospective patient cohorts treated with radiotherapy were included in the study. Cohort A consisted of 26 consecutive patients with a planning 4DCT scan (CT1) and a surveillance 4DCT scan (CT2) at fraction ten. Read More

View Article and Full-Text PDF

Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO).

Acta Oncol 2022 Jun 27:1-7. Epub 2022 Jun 27.

Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.

Background: Nonepithelial ovarian cancer (NEOC) represents a wide variety of rare tumors. They are often diagnosed at an early stage and have a good prognosis compared to epithelial ovarian cancer. In the Nordic countries, the total annual number of patients diagnosed with ovarian cancer, Fallopian tube cancer or primary peritoneal carcinoma (hereafter ovarian cancer) was 2281 in 2014-2018, of which 3-10% were NEOC. Read More

View Article and Full-Text PDF

A nationwide study on characteristics and outcome of cancer patients with sepsis requiring intensive care.

Acta Oncol 2022 Jun 26:1-9. Epub 2022 Jun 26.

Department of Anaesthesia and Intensive Care, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.

Background: Sepsis is the leading cause of admission to the intensive care unit (ICU) for cancer patients and survival rates have historically been low. The aims of this nationwide cohort study were to describe the characteristics and outcomes of cancer patients admitted to the ICU with sepsis compared with other sepsis patients requiring ICU admission.

Material And Methods: This was a retrospective, observational study. Read More

View Article and Full-Text PDF

Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study.

Acta Oncol 2022 Jul 13;61(7):793-800. Epub 2022 Jun 13.

Department of Oncology, Oslo University Hospital, Oslo, Norway.

Background: Data from the real-world setting on perioperative chemotherapy in high-risk, localized soft tissue sarcoma (STS) is limited. Real-world data (RWD) includes data derived from patients treated outside clinical trials and often captures long-term follow-up not recorded in clinical trials. The aim of this study was to provide population-based, real-world evidence on perioperative chemotherapy in localized STS. Read More

View Article and Full-Text PDF

Timing of radiotherapy and chemotherapy start for patients treated with definitive concurrent chemoradiation for head and neck cancer.

Acta Oncol 2022 Jun 12:1-7. Epub 2022 Jun 12.

Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA.

Background: The ideal timing for the initiation of chemotherapy and radiation therapy (RT) in the use of definitive chemoradiation (CRT) for patients with head and neck cancer is not well established. We sought to evaluate the impact of the timing of initiating these two modalities on clinical outcomes.

Materials And Methods: Patients with squamous cell carcinoma of the head and neck who were treated using definitive chemoradiation from 2012 to 2018 were identified. Read More

View Article and Full-Text PDF

Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin.

Acta Oncol 2022 Jul 11;61(7):801-808. Epub 2022 Jun 11.

Department of Clinical Physiology and Nuclear Medicine, Herlev University Hospital, Herlev, Denmark.

Background: Anthracycline induced cardiotoxicity is well recognized but only few data exist in sarcoma patients. This study retrospectively aimed to analyze sequential Cadmium Zinc Telluride (CZT)-multigated equilibrium radionuclide angiography (ERNA) for monitoring left ventricular ejection fraction (LVEF) and to assess the real-life incidence of cardiotoxicity in sarcoma patients receiving doxorubicin based chemotherapy.

Materials And Methods: A retrospective analysis was performed on all sarcoma patients referred to Herlev University Hospital between 2012 and 2015. Read More

View Article and Full-Text PDF

Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.

Acta Oncol 2022 Jun 6:1-8. Epub 2022 Jun 6.

Radiation Oncology Clinical Department, Centro Nazionale di Adronterapia Oncologica (CNAO), Pavia, Italia.

Introduction: Hodgkin lymphoma (HL) is a highly curable hematological malignancy. Consolidation radiation therapy techniques have made significant progresses to improve organ-at-risk sparing in order to reduce late radiation-induced toxicity. Recent technical breakthroughs notably include intensity modulated proton therapy (IMPT), which has demonstrated a major dosimetric benefit at the cardiac level for mediastinal HL patients. Read More

View Article and Full-Text PDF

Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis.

Acta Oncol 2022 Jun 6:1-8. Epub 2022 Jun 6.

Department of Urology, Urological Research Unit, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Background: Symptoms and treatment of benign prostatic hyperplasia (BPH) or erectile dysfunction (ED) may lead to prostate cancer workup, and patterns of prescriptions before diagnosis may affect findings of pharmacoepidemiological studies. Usage of BPH and ED drugs after diagnosis may be related to prostate cancer treatment. We investigated differences in prescription rates of BPH and ED drugs among prostate cancer patients and cancer-free comparisons and between patients with localized and non-localized disease. Read More

View Article and Full-Text PDF

Cancer in the Faroe Islands from 1960-2019 - incidence, mortality, and comparisons with the other Nordic countries.

Acta Oncol 2022 Jun 3:1-9. Epub 2022 Jun 3.

Center of Health Science, University of the Faroe Islands, Tórshavn, Faroe Islands.

In this paper, we present age-standardized cancer incidence and mortality rates in the Faroe Islands. We also compare with the Nordic rates and show incidence rate ratios (IRR) and mortality rate ratios (MRR). The Faroese cancer registry (FCR) was established in 1994, with incidence available from 1960 and mortality from 1983. Read More

View Article and Full-Text PDF

Early intervention with compression garments prevents progression in mild breast cancer-related arm lymphedema: a randomized controlled trial.

Acta Oncol 2022 Jul 3;61(7):897-905. Epub 2022 Jun 3.

Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden.

Background: Early diagnosis and compression treatment are important to prevent progression in breast cancer-related arm lymphedema (BCRAL). However, some mild BCRAL can be reversible, and therefore, compression treatment may not be needed. The aim of this study was to investigate the proportion of women with mild BCRAL showing progression/no progression of lymphedema after treatment with or without compression garments, differences in changes of lymphedema relative volume (LRV), local tissue water and subjective symptoms during 6 months. Read More

View Article and Full-Text PDF

Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.

Acta Oncol 2022 Jul 3;61(7):856-863. Epub 2022 Jun 3.

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.

Purpose: We tested the hypothesis that gene expressions from biopsies of locally advanced head and neck squamous cell carcinoma (HNSCC) patients can supplement dose-volume parameters to predict dysphagia and xerostomia following primary radiochemotherapy (RCTx).

Material And Methods: A panel of 178 genes previously related to radiochemosensitivity of HNSCC was considered for nanoString analysis based on tumour biopsies of 90 patients with locally advanced HNSCC treated by primary RCTx. Dose-volume parameters were extracted from the parotid, submandibular glands, oral cavity, larynx, buccal mucosa, and lips. Read More

View Article and Full-Text PDF

Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia.

Acta Oncol 2022 Jul 1;61(7):849-855. Epub 2022 Jun 1.

Amsterdam UMC location University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Introduction: The recent POLDER trial investigated the effects of external beam radiotherapy (EBRT) on dysphagia caused by incurable oesophageal cancer. An estimated life expectancy of minimally three months was required for inclusion. However, nearly one-third of the included patients died within three months. Read More

View Article and Full-Text PDF

Second primary cancer following primary oral squamous cell carcinoma: a population-based, retrospective study.

Acta Oncol 2022 May 27:1-6. Epub 2022 May 27.

Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Background: Second primary cancer (SPC), defined as a metachronous solid cancer resulting from neither a recurrence of the primary cancer nor a metastasis, is a leading long-term cause of death for survivors of primary oral squamous cell carcinoma (OSCC). This study examined the risk of SPC following treatment of primary OSCC.

Materials And Methods: This semi-national, population-based, retrospective study included all patients with primary OSCC treated with curative intent in Eastern Denmark in 2000-2014. Read More

View Article and Full-Text PDF

Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment.

Acta Oncol 2022 07 27;61(7):824-829. Epub 2022 May 27.

Clinical and Experimental Pathology, Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden.

View Article and Full-Text PDF

Ovarian tumor frozen section, a multidisciplinary affair.

Acta Oncol 2022 Jul 25;61(7):785-792. Epub 2022 May 25.

Division of Oncology, Department of Clinical Science, Skåne University Hospital, Lund University, Lund, Sweden.

Background: Ovarian Cancer (OC) constitute the eighth most common cancers among women worldwide. Surgery remains the cornerstone in the management of OC. Intraoperative frozen section (FS) diagnosis is widely used to decide the surgery course. Read More

View Article and Full-Text PDF

Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression.

Acta Oncol 2022 Jul 25;61(7):833-841. Epub 2022 May 25.

Division of Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.

Background: The effectiveness of abdominal compression for motion management in hepatobiliary-pancreatic (HPB) radiotherapy has not been systematically evaluated.

Methods & Materials: A systematic review was carried out using PubMed/Medline, Cochrane Library, Web of Science, and CINAHL databases up to 1 July 2021. No date restrictions were applied. Read More

View Article and Full-Text PDF

Long-term resource utilisation and associated costs of exercise during (neo)adjuvant oncological treatment: the Phys-Can project.

Acta Oncol 2022 Jul 24;61(7):888-896. Epub 2022 May 24.

Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Background: Exercise during oncological treatment is beneficial to patient health and can counteract the side effects of treatment. Knowledge of the societal costs associated with an exercise intervention, however, is limited. The aims of the present study were to evaluate the long-term resource utilisation and societal costs of an exercise intervention conducted during (neo)adjuvant oncological treatment in a randomised control trial (RCT) versus usual care (UC), and to compare high-intensity (HI) versus low-to-moderate intensity (LMI) exercise in the RCT. Read More

View Article and Full-Text PDF

Cancer in young adulthood - classifying the intensity of treatment.

Acta Oncol 2022 07 15;61(7):809-813. Epub 2022 May 15.

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

View Article and Full-Text PDF

Is there a place for definitive radiotherapy in the treatment of unresectable soft-tissue sarcoma? A systematic review.

Acta Oncol 2022 Jun 15;61(6):720-729. Epub 2022 May 15.

Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.

Background: Definitive external beam radiotherapy (EBRT) is an unusual treatment of unresectable soft-tissue sarcomas (STS). Recent technical innovations and physical advantages of particle therapies may improve results of this therapeutic option. The role of this review was to report the clinical results of photon- and particle-based EBRT in unresectable STS. Read More

View Article and Full-Text PDF

Cluster model incorporating heterogeneous dose distribution of partial parotid irradiation for radiotherapy induced xerostomia prediction with machine learning methods.

Acta Oncol 2022 Jul 9;61(7):842-848. Epub 2022 May 9.

Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Purpose: A cluster model incorporating heterogeneous dose distribution within the parotid gland was developed and validated retrospectively for radiotherapy (RT) induced xerostomia prediction with machine learning (ML) techniques.

Methods: Sixty clusters were obtained at 1 Gy step size with threshold doses ranging from 1 to 60 Gy, for each of the enrolled 155 patients with HNC from three institutions. Feature clusters were selected with the neighborhood component analysis (NCA) and subsequently fed into four supervised ML models for xerostomia prediction comparison: support vector machines (SVM), k-nearest neighbor (kNN), naïve Bayes (NB), and random forest (RF). Read More

View Article and Full-Text PDF

Practical lessons from treating medullary thyroid carcinoma patients harboring a RET-alteration: Pralsetinib-induced acute confusional state.

Acta Oncol 2022 07 9;61(7):819-823. Epub 2022 May 9.

Neuroendocrine Tumor Unit, ENETS Center of Excellence, Endocrinology and Metabolism Department, Hadassah Medical Organization and Faculty of Medicine, Jerusalem, Israel.

View Article and Full-Text PDF

Brain metastases in patients with ovarian cancer.

Acta Oncol 2022 Jun 29;61(6):757-763. Epub 2022 Apr 29.

Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Background: Brain metastasis (BM) are uncommon among women with epithelial ovarian cancer (EOC). The frequency, risk factors and clinical repercussions of BM in these patients are not well described.

Methods: We retrospectively evaluated EOC patients treated at our center from 2002 to 2020 and assessed their clinical parameters, risk for BM development and association with overall survival (OS). Read More

View Article and Full-Text PDF

Comparing Iridium-192 with Cobalt-60 sources in high-dose-rate brachytherapy boost for localized prostate cancer.

Acta Oncol 2022 Jun 29;61(6):714-719. Epub 2022 Apr 29.

Department of Radiation Oncology, University of Wuerzburg, Wuerzburg, Germany.

Background: Dosimetric and clinical comparison of two cohorts of Iridium-192 (Ir-192) and Cobalt-60 (Co-60) high-dose-rate brachytherapy (DR-BT) boost for localized prostate cancer.

Material And Methods: Patients with localized prostate cancer receiving either Ir-192 or Co-60 high-dose-rate brachytherapy (HDR-BT) boost in combination with external beam radiotherapy (EBRT) in the period of 2002-2019 were evaluated for dosimetric differences, side effects, biochemical relapse-free survival (bRFS), metastasis-free survival (MFS), and overall survival (OS). EBRT, delivered in 46 Gy (D) in conventional fractionation, was followed by two fractions HDR-BT boost with 9 Gy (D) 2 and 4 weeks after EBRT. Read More

View Article and Full-Text PDF

Electrochemotherapy for metastatic cutaneous melanoma.

Acta Oncol 2022 05 29;61(5):531-532. Epub 2022 Apr 29.

Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.

View Article and Full-Text PDF